Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2008

01-03-2008 | Original Paper

Effect of Angiotensin-converting Enzyme Inhibition on Experimental Hepatic Fibrogenesis

Authors: Cansel Türkay, Özlem Yönem, Sema Arıcı, Ayhan Koyuncu, Mehmet Kanbay

Published in: Digestive Diseases and Sciences | Issue 3/2008

Login to get access

Abstract

The renin-angiotensin system is suggested to be important in liver fibrogenesis. It induces hepatic stellate cell proliferation and up-regulates transforming growth factor beta-1 (TGF-β1) expression. Matrix metalloproteinase-2 (MMP-2) is involved in extracellular matrix remodelling. Fibrosis, a consequence of most chronic liver diseases, may be the result of a disturbed balance between fibrogenesis and fibrolysis. The aim of this study was to investigate the effect of enalapril on liver fibrogenesis induced in rats by bile-duct ligation. Forty-seven rats were divided into two groups: bile-duct ligated (BDL) (n = 24) and BDL + enalapril (n = 23). Fibrosis was evaluated by the Knodell scoring system, and TGF-β1 and MMP-2 were assessed with immunohistochemistry at the second, fourth and sixth weeks after bile-duct ligation. In the BDL group, TGF-β1 increased by the second week and this increase continued through weeks 4 and 6. In the BDL + enalapril group, TGF-β1 was significantly lower than the other group (P < 0.05). MMP-2 progressively decreased after week 2 in the BDL group. In the BDL + enalapril group, MMP-2 was significantly higher than the BDL group at the fourth and sixth weeks. These results suggest that enalapril reduces the liver tissue TGF-β1 and has an ameliorating effect on the fibrosis markers TGF-β1 and MMP-2.
Literature
1.
go back to reference Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJ, Iredale JP, Mann DA (2001) Glitoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 121:685–698PubMedCrossRef Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJ, Iredale JP, Mann DA (2001) Glitoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 121:685–698PubMedCrossRef
2.
go back to reference Knittel T, Kobold D, Saile B, Grundmann A, Neubauer K, Piscaglia F, Ramadori G (1999) Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 117:1205–1221PubMedCrossRef Knittel T, Kobold D, Saile B, Grundmann A, Neubauer K, Piscaglia F, Ramadori G (1999) Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 117:1205–1221PubMedCrossRef
3.
go back to reference Kawada N (2004) Molecular mechanism of stellate activation and therapeutic strategy for liver fibrosis. Comp Hepatol 3(Suppl 1):S3PubMedCrossRef Kawada N (2004) Molecular mechanism of stellate activation and therapeutic strategy for liver fibrosis. Comp Hepatol 3(Suppl 1):S3PubMedCrossRef
4.
go back to reference Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodes J (2000) Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118:1149–1156PubMedCrossRef Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodes J (2000) Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118:1149–1156PubMedCrossRef
5.
go back to reference Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H (2001) Angiotensin II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34:745–750PubMed Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H (2001) Angiotensin II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34:745–750PubMed
6.
go back to reference Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, Iwao H (1995) Angiotensin II type 1 receptor antagonist inhibits the gene expression of transforming growth factor beta-1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 273:509–515PubMed Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, Iwao H (1995) Angiotensin II type 1 receptor antagonist inhibits the gene expression of transforming growth factor beta-1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 273:509–515PubMed
7.
go back to reference Lee LK, Meyer TW, Pollock AS, Lovett DH (1995) Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96:953–964PubMedCrossRef Lee LK, Meyer TW, Pollock AS, Lovett DH (1995) Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96:953–964PubMedCrossRef
8.
go back to reference Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM (2001) Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121:148–155PubMedCrossRef Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM (2001) Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121:148–155PubMedCrossRef
9.
go back to reference Murawaki Y, Yamada S, Ikuta Y, Kawasaki H (1999) Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol 30:1090–1098PubMedCrossRef Murawaki Y, Yamada S, Ikuta Y, Kawasaki H (1999) Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol 30:1090–1098PubMedCrossRef
10.
go back to reference Watanabe T, Niioka M, Ishikawa A, Hozowa S, Arai M, Maruyama K, Okada A, Okazaki I (2001) Dynamic change of cells expressing MMP-2 mRNA and MT1-MMP mRNA in the recovery from liver fibrosis in the rat. J Hepatol 35:465–473PubMedCrossRef Watanabe T, Niioka M, Ishikawa A, Hozowa S, Arai M, Maruyama K, Okada A, Okazaki I (2001) Dynamic change of cells expressing MMP-2 mRNA and MT1-MMP mRNA in the recovery from liver fibrosis in the rat. J Hepatol 35:465–473PubMedCrossRef
11.
go back to reference Weiner FR, Czaja MJ, Giambrone MA, Takahashi S, Biempica L, Zern MA (1987) Transcriptional and posttranscriptional effects of dexamethasone on albumin and procollagen messenger RNAs in murine schistosomiasis. Biochemistry 26:1557–1562PubMedCrossRef Weiner FR, Czaja MJ, Giambrone MA, Takahashi S, Biempica L, Zern MA (1987) Transcriptional and posttranscriptional effects of dexamethasone on albumin and procollagen messenger RNAs in murine schistosomiasis. Biochemistry 26:1557–1562PubMedCrossRef
12.
go back to reference Czaja MJ, Weiner FR, Eghbali M, Giambrone MA, Eghbali M, Zern MA (1987) Differential effects of g-interferon on collagen and fibronectin gene expression. J Biol Chem 262:1348–1351 Czaja MJ, Weiner FR, Eghbali M, Giambrone MA, Eghbali M, Zern MA (1987) Differential effects of g-interferon on collagen and fibronectin gene expression. J Biol Chem 262:1348–1351
13.
go back to reference Kerchenobich D, Vargas F, Garcia-Tsao G, Perz Tamayo R, Gent M, Rojkind M (1988) Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 318:1709–1713CrossRef Kerchenobich D, Vargas F, Garcia-Tsao G, Perz Tamayo R, Gent M, Rojkind M (1988) Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 318:1709–1713CrossRef
14.
go back to reference Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE (1997) Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin angiotensin system. Kidney Int 51:1553–1567PubMedCrossRef Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE (1997) Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin angiotensin system. Kidney Int 51:1553–1567PubMedCrossRef
15.
go back to reference De Carvalho Frimm C, Sun Y, Weber KT (1997) Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med 129:439–446PubMedCrossRef De Carvalho Frimm C, Sun Y, Weber KT (1997) Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med 129:439–446PubMedCrossRef
16.
17.
go back to reference Ohishi T, Saito H, Tsusaka K, Toda K, Inagaki H, Hamada Y, Kumagai Y, Atsukawa K, Ishii H (2001) Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol Res 21:147–158PubMedCrossRef Ohishi T, Saito H, Tsusaka K, Toda K, Inagaki H, Hamada Y, Kumagai Y, Atsukawa K, Ishii H (2001) Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol Res 21:147–158PubMedCrossRef
18.
go back to reference Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F (2002) Enalapril prevents fatty liver in nephrotic rats. J Nephrol 15:358–367PubMed Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F (2002) Enalapril prevents fatty liver in nephrotic rats. J Nephrol 15:358–367PubMed
19.
go back to reference Wei HS, Lu HM, Li DG, Zhan YT, Wang ZR, Huang X, Cheng JL, Xu OF (2000) The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CCl4. World J Gastroenterol 6:824–828PubMed Wei HS, Lu HM, Li DG, Zhan YT, Wang ZR, Huang X, Cheng JL, Xu OF (2000) The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CCl4. World J Gastroenterol 6:824–828PubMed
20.
go back to reference Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, Rumble JR, Kelly DJ, Tikellis C, Cox A, Smallwood RA, Angus PW (2001) Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 35:376–385PubMedCrossRef Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, Rumble JR, Kelly DJ, Tikellis C, Cox A, Smallwood RA, Angus PW (2001) Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 35:376–385PubMedCrossRef
21.
go back to reference Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H (2003) An angiotensin II type 1 receptor antagonist, olmesartan medoxamil improves experimental liver fibrosis by suppress of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 139(6):1085–1094PubMedCrossRef Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H (2003) An angiotensin II type 1 receptor antagonist, olmesartan medoxamil improves experimental liver fibrosis by suppress of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 139(6):1085–1094PubMedCrossRef
22.
go back to reference Lichtinghagen R, Michels D, Haberkorn CI, Arndt B, Bahr M, Flemming P, Manns MP, Boeker KH (2001) Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol 34:239–247PubMedCrossRef Lichtinghagen R, Michels D, Haberkorn CI, Arndt B, Bahr M, Flemming P, Manns MP, Boeker KH (2001) Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol 34:239–247PubMedCrossRef
23.
go back to reference Lee H, Huang G (2001) Less reversal of liver fibrosis after prolonged carbon tetrachloride injection. Hepatogastroenterology 48:1312–1315PubMed Lee H, Huang G (2001) Less reversal of liver fibrosis after prolonged carbon tetrachloride injection. Hepatogastroenterology 48:1312–1315PubMed
24.
go back to reference Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A, Watanabe A (1995) Increased expression of matrix metalloproteinase II in experimental liver fibrosis in rats. Hepatology 21:787–794PubMedCrossRef Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, Sato H, Seiki M, Ooshima A, Watanabe A (1995) Increased expression of matrix metalloproteinase II in experimental liver fibrosis in rats. Hepatology 21:787–794PubMedCrossRef
25.
go back to reference Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A (1997) Dual expression of matrix metalloproteinase II and membrane type-1 matrix metalloproteinase in fibrotic human livers. Hepatology 26:1521–1529PubMedCrossRef Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A (1997) Dual expression of matrix metalloproteinase II and membrane type-1 matrix metalloproteinase in fibrotic human livers. Hepatology 26:1521–1529PubMedCrossRef
Metadata
Title
Effect of Angiotensin-converting Enzyme Inhibition on Experimental Hepatic Fibrogenesis
Authors
Cansel Türkay
Özlem Yönem
Sema Arıcı
Ayhan Koyuncu
Mehmet Kanbay
Publication date
01-03-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9941-y

Other articles of this Issue 3/2008

Digestive Diseases and Sciences 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.